Loading...
•
Dec 31, 2019
ACADIA Q4 2019 Earnings Report
Reported strong financial results for the fourth quarter and full year ended December 31, 2019.
Key Takeaways
ACADIA Pharmaceuticals reported Q4 2019 net sales of NUPLAZID® were $98.3 million, an increase of 65% compared to Q4 2018. The company's net loss for the quarter was $53.0 million, or $0.34 per common share, compared to a net loss of $65.5 million, or $0.50 per common share, for the same period in 2018.
NUPLAZID net sales increased by 65% compared to Q4 2018.
Net loss decreased compared to the same period in 2018.
The company is on track to submit a supplemental NDA for dementia-related psychosis in the summer of 2020.
The company expects to announce top-line results from its Phase 3 CLARITY-2 study of pimavanserin as an adjunctive treatment for major depressive disorder in the fourth quarter of 2020.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.com Forward Guidance
ACADIA provides 2020 net sales guidance for NUPLAZID to be between $440 and $470 million.
Positive Outlook
- NUPLAZID net sales are expected to be between $440 and $470 million.
- GAAP R&D is expected to be between $270 and $285 million.
- GAAP SG&A is expected to be between $440 and $460 million.
- Non-cash stock-based compensation expense is expected to be between $90 and $100 million.
- 2020 year-end cash, cash equivalents, and investment securities are expected to be between $470 and $500 million.